Macular Disease Foundation Australia logo

    COVID-19 announcement

    Essential patient and carer information

    Image of a man smliing at the camera

    COVID-19: Let’s beat this together

    In 2020, the world has changed rapidly with the spread of the coronavirus known as COVID-19.  This rapid change can create anxiety and uncertainty as we make the necessary changes in our daily lives to fight this unprecedented event.  

    There’s a lot of new health information to understand. And it is changing day by day. We understand that this situation can be particularly frightening for those in our community who are elderly, have vision loss, or who have other health conditions that make them more vulnerable to the virus. 

    It’s important to know that the Macular Disease Foundation Australia, although working remotely, is still here to support the macular disease community and their families.  At a time like this, it’s important to remain connected as a community. It’s also important for you to know that support is never more than a phone call or email away.

    It is essential for people receiving intravitreal injections to maintain their scheduled appointments with their ophthalmologists during this time. 

    In the current COVID-19 environment, intravitreal injections are essential health services. 

    If you have any concerns about ongoing treatment, you should contact your ophthalmologist immediately.

    We are ready and waiting to support you and your families with updated news and information about all aspects of maintaining eye health during this pandemic.  We can be contacted Monday to Friday 9am to 5pm (AEST).

    National Helpline

    1800 111 709

    Our social media channels are also a great way to reach out to us and have conversations with others.

    We’ll also provide you with up-to-date information that is relevant to keeping your vision safe, during these uncertain times on website. Please continue to be engaged with our digital platforms as a source of correct information relevant to the macular disease community.

    Posted: 27 March 2020

    More articles like this